TY - JOUR
T1 - Desensitization With Imlifidase for HLA-Incompatible Deceased Donor Kidney Transplantation
T2 - A Delphi International Expert Consensus
AU - Furian, Lucrezia
AU - Heemann, Uwe
AU - Bengtsson, Mats
AU - Bestard, Oriol
AU - Binet, Isabelle
AU - Böhmig, Georg A.
AU - Boletis, John
AU - Briggs, David
AU - Claas, Frans H.J.
AU - Couzi, Lionel
AU - Cozzi, Emanuele
AU - Crespo, Marta
AU - De Vries, Aiko P.J.
AU - Diekmann, Fritz
AU - Durlik, Magdalena
AU - Glotz, Denis
AU - Helantera, Ilkka
AU - Jackson, Annette
AU - Jordan, Stanley C.
AU - Kuypers, Dirk
AU - Lefaucheur, Carmen
AU - Legendre, Christophe
AU - Lorant, Tomas
AU - Maggiore, Umberto
AU - Mamode, Nizam
AU - Marinaki, Smaragdi
AU - Massart, Annick
AU - Müller, Thomas
AU - Oberbauer, Rainer
AU - Renders, Lutz
AU - Roelen, Dave
AU - Taupin, Jean Luc
AU - Viklický, Ondřej
AU - Vittoraki, Angeliki
AU - de Weerd, Annelies E.
AU - Naesens, Maarten
N1 - Publisher Copyright:
Copyright © 2025 Furian, Heemann, Bengtsson, Bestard, Binet, Böhmig, Boletis, Briggs, Claas, Couzi, Cozzi, Crespo, De Vries, Diekmann, Durlik, Glotz, Helantera, Jackson, Jordan, Kuypers, Lefaucheur, Legendre, Lorant, Maggiore, Mamode, Marinaki, Massart, Müller, Oberbauer, Renders, Roelen, Taupin, Viklický, Vittoraki, de Weerd and Naesens.
PY - 2025/1/6
Y1 - 2025/1/6
N2 - Highly sensitized (HS) patients in need of kidney transplantation (KTx) typically spend a longer time waiting for compatible kidneys, are unlikely to receive an organ offer, and are at increased risk of antibody-mediated rejection (AMR). Desensitization using imlifidase, which is more rapid and removes total body immunoglobulin G (IgG) to a greater extent than other methods, enables transplantation to occur between HLA-incompatible (HLAi) donor–recipient pairs and allows patients to have greater access to KTx. However, when the project was launched there was limited data and clinical experience with desensitization in general and with imlifidase specifically. Hence, this Delphi methodology was used to reach a consensus from a multi-disciplinary team (MDT) of experts from 15 countries on the management of HS patients undergoing imlifidase HLAi from a deceased donor (DD) KTx. This Delphi consensus provides clinical practice guidance on the use of imlifidase in the end-to-end management of HS patients undergoing an HLAi DD KTx and supports centers in the development of guidelines for the utilization and integration of imlifidase into clinical practice.
AB - Highly sensitized (HS) patients in need of kidney transplantation (KTx) typically spend a longer time waiting for compatible kidneys, are unlikely to receive an organ offer, and are at increased risk of antibody-mediated rejection (AMR). Desensitization using imlifidase, which is more rapid and removes total body immunoglobulin G (IgG) to a greater extent than other methods, enables transplantation to occur between HLA-incompatible (HLAi) donor–recipient pairs and allows patients to have greater access to KTx. However, when the project was launched there was limited data and clinical experience with desensitization in general and with imlifidase specifically. Hence, this Delphi methodology was used to reach a consensus from a multi-disciplinary team (MDT) of experts from 15 countries on the management of HS patients undergoing imlifidase HLAi from a deceased donor (DD) KTx. This Delphi consensus provides clinical practice guidance on the use of imlifidase in the end-to-end management of HS patients undergoing an HLAi DD KTx and supports centers in the development of guidelines for the utilization and integration of imlifidase into clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85216444562&partnerID=8YFLogxK
U2 - 10.3389/ti.2024.13886
DO - 10.3389/ti.2024.13886
M3 - Article
C2 - 39867871
AN - SCOPUS:85216444562
SN - 0934-0874
VL - 37
JO - Transplant International
JF - Transplant International
M1 - 13886
ER -